RAMIFENTANYL
Arrhythmia, Cardiac
Medical University of WarsawSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Arrhythmia, Cardiac cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CISATRACURIUM ION Medical University of Warsaw | Phase 4 | BB |
SUFENTANIL CITRATE Medical University of Warsaw | Phase 4 | BB |
PROPOFOL Medical University of Warsaw | Phase 4 | BB |
Desflurane Medical University of Warsaw | Phase 4 | BB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Medical University of Warsaw | Phase 4 | BB |
FENTANYL Medical University of Warsaw | Phase 4 | BB |
Same molecule, other indications
RAMIFENTANYL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →